



11 4 pg, 1.31.02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT

: JACKOWSKI et al.

INVENTION:

: DIAGNOSIS AND TREATMENT OF EARLY
PRE-TYPE-1 DIABETES UTILIZING GLIAL
FIBRILLARY ACIDIC PROTEIN

SERIAL NUMBER

: 09/954,972

FILING DATE

: September 17, 2001

EXAMINER:

: (not assigned yet)

GROUP ART UNIT

: 1646

ATTORNEY DOCKET NO.

: 2132.074

INFORMATION DISCLOSURE STATEMENT

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 12-14-01

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the
accompanying form PTO-1449 are hereby brought to the attention of the Examiner for
independent evaluation. A copy of each reference is enclosed. The references were cited in the
specification and their relevancy is set forth therein.

Applicants submit that the present invention is patentable over these references.

Respectfully Submitted,

Date:

12/14/2001

Ferris H. Lander

Reg. No. 43,377

McHale & Slavin, P.A.

4440 PGA Boulevard, Suite 402

Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575

Form PTO-1449
(Rev. 2-88)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2132.074APPLICATION NO.
09/954,972INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
JACKOWSKI et al.FILING DATE
09/17/01GROUP
1646

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Rossini et al., Animal models of human disease, Clin. Immunol. Immunopathol., (1995) 74, pp.2-9.
		Winer et al., Peptide dose, MHC affinity, and target self-antigen expression are critical for effective immunotherapy of nonobese diabetic mouse prediabetes, J. Immunol., (2000) 165, pp.4086-4094.
		Winer et al., Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; Nonimmunized nonobese diabetic mice can develop autoimmune encephalitis, J. Immunol., (2001) 166, pp.2831-2841.
		Winer et al., T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice., J. Immunol., (2001) 166, pp.4751-4756.
		Lipton et al., Autoimmunity and genetics contribute to the risk of insulin-dependent diabetes mellitus in families: Islet cell antibodies and HLA DQ heterodimers., Amer. J. Epidemiol., (1992) 136, 5, pp.503-512.
		Verge et al., Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes., Diabetes, 47, pp.1857-1866.
		Karges et al., Self and non-self antigen in diabetic autoimmunity: Molecules and mechanisms., Molec. Aspects Med., (1995) 16, pp.79-213.
		Donev, Ultrastructural evidence for the presence of a glial sheath investing the islets of langerhans in the pancreas of mammals., Cell and Tissue Research, (1984) 237, pp.343-348.
		Takahashi et al., Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody., Clin. Chem., (1999) 45, 8, pp.1307-1311.
		Atkinson et al., The NOD mouse model of type I diabetes: As good as it gets?, Nat. Med., (1999) 5, 6, pp.601-604.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.